- In April 2023, PacBio, a global leader in Single-Molecule Real-Time Sequencing (SMRT) technology based in the U.S., announced the launch of its latest SMRT sequencing platform aimed at increasing accuracy and throughput for genomic research. This advancement highlights PacBio’s commitment to pushing the boundaries of sequencing technology, enabling researchers worldwide to gain deeper insights into complex genomes with higher efficiency. By integrating innovative chemistry and software improvements, PacBio is reinforcing its leadership in the expanding global SMRT market
- In March 2023, Beijing Genomics Institute (BGI), headquartered in China, unveiled a new SMRT sequencing service tailored for clinical diagnostics and personalized medicine. This initiative emphasizes BGI’s dedication to providing accessible and precise genomic solutions, supporting the advancement of healthcare and biotech industries. The rollout of this service also reflects the growing demand for high-quality sequencing data in Asia-Pacific, bolstering BGI’s position in the competitive SMRT market
- In March 2023, Illumina, a U.S.-based genomic technology company, expanded its SMRT sequencing collaborations with pharmaceutical companies to accelerate drug discovery and biomarker development. These partnerships demonstrate Illumina’s strategic focus on leveraging SMRT sequencing for improving precision medicine and enhancing therapeutic pipelines. This move solidifies Illumina’s role as a key player driving innovation in the SMRT sequencing ecosystem
- In February 2023, Genedata AG, a Switzerland-based bioinformatics firm, announced the integration of advanced SMRT sequencing data analysis capabilities into its software platform. This enhancement is designed to streamline genomic data interpretation for researchers and biotech companies, improving accuracy and reducing analysis time. Genedata’s collaboration with SMRT sequencing providers underscores the growing importance of sophisticated bioinformatics solutions in maximizing the value of SMRT data
- In January 2023, Eurofins Genomics, headquartered in Luxembourg, introduced a new service package combining SMRT sequencing with comprehensive genomic annotation and reporting. This offering provides customers with an end-to-end solution for genomic projects, emphasizing Eurofins’ commitment to supporting scientific discovery and clinical research. The launch reinforces Eurofins’ expanding footprint in the global SMRT sequencing market, catering to diverse research and commercial needs
